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Mutations in residues of TP53 that directly contact DNA
predict poor outcome in human primary breast cancer
EMJJ Berns, IL van Staveren, MP Look, M Smid, JGM Klijn and JA Foekens
Division of Endocrine Oncology (Department of Medical Oncology), Rotterdam Cancer Institute (Daniel den Hoed Kliniek)/University Hospital Rotterdam,
The Netherlands
Summary The tumour-suppressor gene TP53 is frequently mutated in breast tumours, and the majority of the mutations are clustered within
the core domain, the region involved in DNA binding. We searched foralterations in this central domain ofthe TP53gene in 222 human breast
cancer specimens using polymerase chain reaction-single-strand conformation analysis (PCR-SSCA) followed by sequencing. TP53 gene
mutations were observed in 66 tumours (31%), including three tumours that contain two mutations. Fifty-four (78%) of these mutations were
missense point mutations, one was a nonsense mutation and four were deletions and/or insertions causing disruption of the protein reading
frame, whereas four mutations were either silent or a polymorphism (at codon 213; n = 6). Interestingly, the majority of missense mutations
were observed at codon 248. The outcome has been related with patient and tumour characteristics, and with prognosis in 177 patients who
were eligible for analysis of both relapse-free and overall survival (median survival for patients alive was 115 months). There was no
significant association between the frequency of TP53 mutations and menopausal or nodal status, or tumour size. In a Cox univariate
analysis, TP53 gene mutation was significantly associated with poor relapse-free survival (RFS: P = 0.02) but not with overall survival (OS:
P= 0.07). In a Cox multivariate analysis, including classical prognostic factors, TP53gene mutation independently predicted poor RFS and OS
(RHR = 1.8 and 1.6 respectively). Unexpectedly, the median relapse-free survival of patients with a polymorphism at codon 213 or with a
silent mutation was shorter (median 11 months) than the median relapse-free survival of patients with or without a TP53 gene mutation
(median 34 or 48 months respectively). In an exploratory subset analysis, mutations in codons that directly contact DNA were related with the
poorest relapse-free (P< 0.05) and overall survival (P< 0.02). These data imply that in the analysis of the prognostic value of TP53, the type
of mutation and its biological function should be considered.
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The tumour-suppressor gene TP53 (also known as p53) plays a
key role in cell cycle regulation, gene transcription, genomic
stability, DNA repair, senescence and apoptosis (reviewed in
Haffner and Oren, 1995; Kinzler and Vogelstein, 1996; Velculescu
and El-Deiry, 1996; Harris, 1996a). Inactivation ofwild-type func-
tions of TP53 by either mutation of the gene, nuclear exclusion,
interaction of its protein product with either cellular proteins (for
example MDM2) or oncogene products of DNA tumour viruses
can lead to cancer (Levine et al, 1991). Point mutation is the most
common event and as this is often accompanied by deletion ofthe
second allele, all wild-type TP53 activity will be eliminated.
The structure-function relationship of the TP53 protein
provided a basis for understanding how TP53 mutations might
inactivate its normal cell function. The central portion of TP53
consists ofthree loops involved in DNA binding (Cho et al, 1994).
Most mutations are clustered within the core domain (residues
102-292) and mutations are particularly common in the four
conserved regions located in this core domain (Cariello et al, 1994;
Greenblatt et al, 1994; Harris, 1996b). In general, these mutations
are missense (Cariello et al, 1994), resulting in a defective or
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conformationally altered non-functional protein (Harris, 1996b).
Up to 20% of the mutations, however, have been reported outside
exons 5-8, and these are predominantly of the 'null type' (Bergh
et al, 1995; Hartmann et al, 1995). There are two functional classes
ofmutations, ofwhich class I affects residues that directly contact
DNA (for example hotspots Arg-248 and Arg-273) and of which
class II affects residues that have a critical role in stabilizing the
structural integrity of the domain (for example hotspot Arg-175)
(Prives, 1994).
TP53 gene mutation is the most common single gene alteration
in breast cancer and, depending on the method of detection, the
frequencies of TP53 mutations reported in invasive breast cancer
range from 12% to 46% (Andersen and B0rresen, 1995). The tran-
sitions ofthe major CpG dinucleotide hotspots at codons 175, 248
and 273 are the most prevalent (Cariello et al, 1994; Greenblatt
et al, 1994; Hartmann et al, 1997). In general, TP53 gene alterations
have been associated with worse prognosis of breast cancer
patients. However, various mutations can alter the TP53 protein
distinctly, which may lead to different biological characteristics
and tumorigenic potential (Cho et al, 1994; Friend, 1994).
Analysis ofthese various mutations allows us to focus attention on
the biological significance ofparticular mutations, which may abet
selection of those residues that could be of predictive value in
breast cancer.
In the present study on breast carcinoma samples, both type and
location of TP53 gene alterations were studied. The outcome, by
function of affected codons and regions, was related with patient
and tumour characteristics and with (relapse-free) survival.
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PATIENTS AND METHODS
Patients and tumour samples
TP53 gene alterations were studied in a series of222 female breast
tumours. Of the patients, 177 were eligible for evaluation of
relapse-free and overall survival according to the strict criteria
described previously (Putten et al, 1996). The 45 patients who were
excluded from the analyses of (relapse-free) survival involved 37
for whom tumour characteristics were unknown and no records
were available and eight for whom follow-up was not detailed
enough. Patients underwent surgical tumour removal (124 mastec-
tomy, 53 lumpectomy) between 1978 and 1990. Radiotherapy on
the breast or thoracic wall was given to 89 patients, ofthe axilla to
81 patients and of other lymph node areas (supraclavicular and/or
parastemal) to 143 patients. The median age ofthese patients was
59 years (range, 28-82 years), 33% were premenopausal, 36% had
no involved lymph nodes, and the majority of the patients had
tumours < 5 cm.
Of the node-positive patients, 39 patients (35%) received
systemic adjuvant therapy (30 patients received CMF; seven
patients tamoxifen and two patients a combination of hormonal
therapy and chemotherapy). One node-negative patient received
systemic adjuvant therapy. These and further details of the
patients, with a medium follow-up ofpatients alive of 115 months
(range, 47-183 months), are given in Table 1. One-hundred and
eight patients (61%) experienced a relapse and 106 patients (60%)
died during follow-up ofthis study.
DNA isolation and sequence analysis
Breast tumour specimens, stored in liquid nitrogen, were pulver-
ized and homogenized in phosphate buffer according to the proce-
dures recommended by the EORTC (EORTC Breast Cancer
Cooperative Group, 1973). High-molecular-weight chromosomal
DNA was isolated from an aliquot of the total tissue homogenate
as described previously (Berns et al, 1992). Exons 5 through 8 of
the TP53 gene were analysed by polymerase chain reaction (PCR)
driven single-strand conformation analysis (PCR-SSCA), as
described previously (Berns et al, 1996). The mammary tumour
cell line EVSA-T was included in the assay as a positive control
for the neutral polymorphism at codon 213 (exon 6), which occurs
in 3-10% ofthe normal population (Carbone et al, 1991). Because
of possible errors that may accumulate in the initial PCR step,
samples showing an altered electrophoretic mobility of single-
stranded nucleic acids were analysed again with an independent
PCR product. A third PCR product was sequenced (Ampli-Cycle
sequencing kit, Perklin Elmer, Branchbury, NJ, USA) with
5-prime 33P end-labelled primers. The DNA sequence was deter-
mined by separation ofthe terminated products on a 6% polyacry-
lamide gel containing 8 M urea, followed by autoradiography. The
naturally occurring restriction sites of HaeII, TaqI and MspI
were used to verify mutations in codons 175 (exon 5), 213
(A-*G polymorphism in exon 6) and 248 (exon 7) respectively.
Luminometric immunoassay
The TP53 protein levels were measured in 151 breast tumour
cytosols, which were available from the cytosol bank, using
a quantitative luminometric immunoassay (LIA; AB Sangtec
Medical, Bromma, Sweden), described previously by us (De Witte
Table 1 Patient characteristics and TP53gene alterations
Characteristics Number of tumours %
with TP53 alterations
Patients with complete
sequence (n = 214) 66 with mutationsa 31
Patients eligible for the analysis
of RFS and OS (n = 177) 53 with mutations 30
Nodal statusb
Node-negative (n= 64) 20 with mutations 31
Node-positive (n= 111) 32 with mutations 29
Tumour sizec
< 2 cm (n = 46) 15 with mutations 33
2-5 cm (n = 95) 25 with mutations 26
> 5 cm (n = 33) 12 with mutations 36
Adjuvant therapy
Yes (n = 40)d 11 with mutations 31
No (n = 137) 42 with mutations 28
Relapse
No (n = 69) 16 with mutations 23
Yes (n = 108) 37 with mutations 34
Survival
Alive (n = 71) 18 with mutations 25
Dead (106) 35 with mutations 33
a In 66 tumour samples, 69 mutations were observed (see text). bNodal
status missing for two patients, one with a mutation. c Tumour size missing
for three patients, one with a mutation. d Of the node-positive patients,
39 patients (35%) received systemic adjuvant therapy (see text). One
node-negative patient received systemic adjuvant therapy.
et al, 1996). In brief, the luminometric immunoassay (LIA) which
detects both wild-type and mutant TP53 protein in a sandwich-
type assay, is based on a combination of two monoclonal anti-
bodies: 1801, as catching antibody, and DOI, as detecting
antibody labelled with the chemiluminescent compound amino-
butyl-ethyl-isoluminol. The immunoassay was performed by
incubating either 100,l of TP53 standard (range: 0-80 ng ml-),
controls or tumour cytosols, as recommended by the supplier.
Statistical analysis
The associations between TP53 mutations and other prognostic
variables were examined using non-parametric tests: the
Kruskall-Wallis test for ordered variables (menopausal status,
grade) and the Spearman's rank correlation(rs) forcontinuous vari-
ables (age, tumour size, nodal status). Two-sided P-values below
0.05 were considered significant. The likelihood ratio test in the
univariate Cox regression model was used to test for differences
and trend. The relapse-free and overall survival probabilities were
calculated by the actuarial method ofKaplan and Meier (1958).
RESULTS
Analysis of TP53gene mutations in 222 breast tumours
Two-hundred and twenty-two female breast tumour specimens
were studied. Altered migration patterns on SSCA, indicative
of TP53 gene mutations, were observed in 77 (35%) samples.
The sequence data were successfully obtained on 214 tumours
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Figure 1 Mutation spectrum of TP53 gene alterations in 222 breast tumours. The four silentmutations [at codons 244, 256, 257 (n = 2)] and the six cases with
neutral polymorphism at codon 213 (exon 6) are shaded. Psr, protein stabilizing region; Zn, Zinc contact; DC, DNA contact. Exon 5, codon 126-186; exon 6,
codon 187-224; exon 7, codon 225-261 and exon 8, codon 262-306
(see Table 1). Sixty-six tumour samples were successfully
sequenced and 69 TP53 gene mutations were found in these 66
tumour samples (see Table 1 and Figure 1). We observed 54
missense point mutations, comprising 78% of all mutations, and
five mutations leading to a premature termination of the protein
[one nonsense mutation (codon 196) and four deletions and/or
insertions (codons 150, 216 and two times at codon 218, in exons
5 and 6)]. As expected, the majority (81%) of the mutations are
transitions, and mutations ofthe amino acid arginine (Arg, n = 20)
are the most prevalent (34%). These mutations were distributed
over 37 distinct codons and resided especially in exon 7 (41%). In
addition, we observed six cases of polymorphism of codon 213
(exon 6) and four silent mutations (codons 244, 256 and two times
codon 257; all within exon 7).
Forty-one out of 59 mutations (69%) were restrained to the
conserved regions, and 25 mutations (42%) were within the zinc-
binding domains (regions L2 and L3; Figure 1). Moreover, our
analysis identified mutations in three of the seven amino acids
important in direct DNA binding (i.e. codons 248, 273 and 280), in
total 16 mutations were observed (Figure 1).
Recently, a LIA became available for the measurement ofTP53
protein levels in cytosolic extracts. This assay, which detects both
wild-type and mutant TP53 protein, is based on the principle that
mutated TP53 has a prolonged half-life and is thus accumulated in
the cell. In a subset of 151 primary breast tumour samples, the LIA
values were related with the outcome of mutation analysis. The
median TP53 level of 4.2 ng mg-' protein (range 0.0-176.0) in 46
tumours with missense mutations was higher (eightfold) than those
levels measured in ten tumours with a silent mutation or in 91
tumours without a TP53 gene alteration [median levels of 0.5
(range 0.0-11.9) or 0.4 (range 0.0-70.8 ng mg-' protein) respec-
tively]. The level in tumours with deletions/insertions, however,
was also low, i.e. 0.1 ng mg-' protein (range 0.0-0.16).
TP53 gene mutations related with tumour and patient
characteristics and (relapse-free) survival of 177
patients
Ofthe 177 patients who were evaluable for analysis ofrelapse-free
survival (RFS) and overall survival (OS), we observed 43 missense
point mutations, four mutations leading to premature termination of
the protein (one nonsense and three deletions and/or insertions)
and six silent alterations in the primary tumours (Table 2). The
frequency of TP53 mutations in the primary tumours was not
significantly related with tumour size or nodal status (Table 1) nor
was there arelation with failure type (Table 2). The median RFS in
the six patients with a mutation at codon 213 (neutral polymor-
phism) or a silent mutation (in exon 7) was shorter (median RFS =
11; range 7-107 months) than the RFS of the 47 patients with a
mutation (median RFS = 34; range 3-160 months) and with the
median RFS of 124 patients with wild-type TP53 (median RFS =
48; range 2-183 months).
In an exploratory analysis the TP53 gene mutations were strati-
fied according to type of mutation, for example evolutionarily
conserved regions, zinc-binding domains L2 (residues 163-195)
and L3 (residues 236-251) of the protein, by residues that directly
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Table 2 Patient and tumour characteristics and TP53gene mutations of patients with follow-up
Number Codona Changeb Liac Age TINd DFS* Site of metastasis;
Effect Site (ng mg P) (years) (months)
Missense
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
127
135
138
145
151
162
163
173
175
175
176
180
205
212
218
220
232
234
234
236
238
238
244
245
245
245
246
248
248
248
248
248
248
254
257
272
273
273
275
280
280
282
307
Ser-4Pro
Cys-+Arg
Ala--Val
Leu-+Arg
Pro-4Ala
lle-Thr
Tyr-4Cys
Val-*Ala
Arg->His
Arg-*His
Cys-*Tyr
Glu--Gly
Tyr-*Phe
Phe-+Leu
Val->Glu
Tyr--Ser
lle-*Ser
Tyr-+Cys
Tyr-*Cys
Tyr-4Cys
Cys-oSer
Cys-Tyr
Gly-*Ser
Gly-oSer
Gly-+Ser
Gly-*Ser
Met-Val
Arg-4Gln
Arg-4Gln
Arg-oGln
Arg-+Gln
Arg-Trp
Arg-Trp
lle-*Ser
Leu-4Pro
Val-+Met
Arg-*His
Arg-+His
Cys-iyr
Arg-*Thr
Arg-Thr
Arg-*Gly
Gly-4Asp
L2
L2
L2/psr
L2/psr
L2/Zn
L2
L3
L3/Zn
L3/Zn
L3
L3/psr
L3/psr
L3/psr
L3
L3/DNA
L3/DNA
L3/DNA
L3/DNA
L3/DNA
L3/DNA
DNA
DNA
DNA
DNA
psr
2.0
5.8
4.2
n.d.
41.9
0.2
0.1
1.2
6.1
1.9
4.8
2.8
11.7
n.d.
13.0
4.1
9.8
0.6
5.8
0.1
nd
0.4
1.7
4.8
2.0
n.d.
n.d.
176.0
49.0
26.3
87.3
n.d.
0.3
n.d.
1.1
9.0
20.6
6.0
12.7
0.2
3.3
5.7
0.3
49
70
67
61
49
64
73
62
40
68
50
55
57
42
75
54
52
46
82
72
62
44
74
50
77
47
52
72
58
70
75
51
57
52
61
34
57
39
53
46
73
59
54
1/1
4/1
2/12
3/0
2/1
1/1
2/1
1/1
2/1
2/0
1/1
1/1
2/1
1/0
2/2
2/0
2/1
1/1
2/0
2/x
2/0
1/1
2/1
3/1
4/1
3/1
1/0
3/1
2/1
3/0
1/1
2/0
3/0
1/0
1/1
2/1
x/1
2/0
2.0
3/0
2/1
2/1
2/0
> 118
4
8
42
3
122
17
> 100
13
>72
60
17
34
36
34
> 122
> 116
>54
> 108
26
30
111
32
14
15
18
> 113
4
6
12
3
46
> 141
> 160
50
10
6
34
> 100
25
23
44
7
SCCI
META
LRR
META
LRR
SCCI
META
META
META
SCCI
META
META
META
META
LRR
META
META
META
META
META
META
META
D-BRCA
META
D-BRCA
META
META
META
META
D-BRCA
META
META
Deletion/insertion/nonsense
Frameshift; 449-467*, 19bp del
Arg-*stop n
Frameshift; 653-657, 5bp d/i 4bp
Frameshift; 654 ins 5bp
Arg-4Arg
Arg-Arg
Arg-*Arg
Arg-Arg
Arg-+Arg
Gly--Gly L3
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150
196
218
218
44
45
46
47
Silent
48
49
50
51
52
53
213
213
213
213
213
244
0.2
n.d.
0.0
n.d.
11.9
0.3
0.7
0.4
0.7
0.0
61
38
54
75
42
77
44
73
68
53
2/0
1/0
4/1
1/0
4/1
3/1
1/1
2/2
2/0
2/0
45
26
21
42
7
9
11
17
> 107
11
META
MAM2
META
D-BRCA
SCCI
META
META
META
SCCI
aDouble mutants, number 8 has an additional frameshift at codon 216 (d/i) and number 25 has an additional mutation at codon 253 (Thr-4Ala). bSite, L2/L3, loop
2 or loop 3; psr, protein stabilizing region; Zn, zinc-binding domain; DNA, direct contact with DNA. Del/d, deletion; insfi, insertion; n, nonsense; *position of base.
CLIA, luminometric immunoassay (see Patients and methods). dT tumour size (1, < 2 cm; 2, 2-5 cm; 3/4, > 5 cm); N, nodal status (0, node negative; 1, node
positive; x, unknown). eDFS, disease-free survival in months. 'Site of relapse: SCCI, distant nodes; META, distant metastasis; LRR, local regional relapse;
D-BRCA, dead without evidence of recurrent disease. Only patients with complete tumour characteristics available were included in this table.
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Table 3 Cox univariate (relapse-free) survival analysis of 177 breast cancer patients, stratified by TP53 mutation type
Five-year RFS Five-year OS
Patient group n RHR 95% CL P-value RHR 95% CL P-value
WT 124 1 1
All mutations 53 1.7 1.1-2.6 0.01 1.8 1.1-2.8 0.02
WT 124 1 1
Non-conserved 19 1.6 0.96-2.6 n.s. 1.8 0.95-3.6 n.s.
Conserved region 34 1.9 1.1-3.5 0.03 1.7 1.0-3.0 0.05
WT 124 1 1
Outside loops 33 1.6 0.95-2.6 n.s. 1.7 0.97-2.9 n.s.
Inside loops, L2 and L3 20 2.0 1.1-3.6 0.02 1.9 1.0-3.8 0.05
WT 124 1 1
Non-direct DNA 43 1.6 1.0-2.5 0.05 1.5 0.93-2.6 n.s.
Direct DNA contact 10 2.7 1.2-5.8 0.02 3.4 1.5-7.6 0.002
WT, wild-type TP53. RHR, relative hazard rate. 95% CL, 95% confidence interval. For the explanation of codons involved in silent mutation, conserved regions,
loops L2 and L3 and direct DNA contact see Figure 1 and Results.
contact DNA (Table 3) and by occurrence ofsilent mutations. Cox
univariate analysis, at 5 years, showed that both the relapse-free
and overall survival ofpatients with TP53 mutations in either the
conserved regions, within L2 and L3, or the codons that directly
contact DNA is significantly worse (relative hazard rate (RHR) for
RFS: 1.9, 2.0, 2.7 and 4.1 respectively; see Table 3) than those
patients without mutations (WT, wild type), or with mutations in
codons that are not conserved or are outside L2 and L3.
Actuarial relapse-free and overall survival curves stratified by
TP53 status revealed that the TP53 gene mutation was signifi-
cantly (P = 0.02) associated with an increased risk ofrelapse with
a RHRof 1.6 [95% confidence interval (CI): 1.1-2.4], but not with
the rate ofdeath [P = 0.07; RHR = 1.5 (CI = 0.97-2.2), shown in
Figure 2A and B]. When stratified as the function oftype of TP53
mutation, only mutations at residues that directly contact DNA
retained significance (RFS: P < 0.05 and OS: P < 0.02, respec-
tively, shown in Figure 2C and D).
In a multivariate Cox regression analysis, which included age,
menopausal status, lymph node status, tumour size, steroid
hormone receptor status and c-MYC amplification, TP53 gene
mutation independently predicts poor RFS and OS with relative
hazard rates of 1.8 (P < 0.01) and 1.6 (P = 0.04) respectively.
DISCUSSION
The present prevalence of TP53 mutations is in the range of the
overall rate ofTP53 mutations of 15-71% (mean 25%; examined in
1452 breast tumour samples worldwide, by SSCA ofexon 5-8, and
reviewed by Hartmann et al, 1997). Evaluation of only exons 5
through 8 may, however, underestimate the overall prevalence of
TP53 mutations by 10-20% (Bergh et al, 1995; Hartmann et al,
1995). The mutations observed in this study resided mainly (41%)
in exon 7. This high incidence is in accordance with the study of
Anderson et al (1993) who also described a predominance of
mutations in exon 7. The mutational 'hotspots' described in breast
cancer (Greenblatt et al, 1994), i.e. codons Arg-175, Arg-248 and
Arg-273 accounted for 3%, 17% and 7%, respectively, in this study.
This differs from the prevalence of 6%, 7%, and 7%, respectively,
summarized in the database established by Cariello et al (1994) on
TP53 gene mutations (n = 365) in human primary breast tumours.
Interestingly, B0rresen et al (1995) also showed a relatively lower
frequency (3%) of mutations in codon 175 and this could imply a
lower prevalence of codon 175 mutations in European women.
When stratifying the mutations according to the evolutionarily
conserved regions or functional domains, we observed that 41 out
of 59 mutations (69%) were restrained to the conserved regions,
which is in concordance with the percentage ofmutations (73%) in
this region summarized by Cariello et al (1994). Bergh et al
(1995), who studied mainly tumours from node-negative patients,
observed a smaller number of mutations in these conserved
regions, i.e. 30 out of 65 (46%). In our smaller number of node-
negative patients 13 out of 21 mutations were in the conserved
regions (62%). Twenty-five mutations (42%) in this study were
within the structural regions L2 and L3, which is in accordance
with data observed by B0rresen et al (1995).
As expected, the median TP53 level of tumours with missense
mutations was higher (eightfold) than levels of tumours with a
silent mutation or without a gene alteration, but also with four
tumours with deletions/insertions. This last result shows that low
levels of TP53 measured by LIA, and probably also by immuno-
histochemistry, are not always indicative of a normal TP53 gene
status and the data should be interpreted with care.
An unexpected finding was that the median RFS in the six
patients with a neutral polymorphism at codon 213 or a silent
mutation was shorter (median RFS = 11 months) than the RFS of
the 47 patients with a mutation (median RFS = 34 months) and
with the median RFS of 124 patients with wild-type TP53 (median
RFS = 48 months). Shiao et al (1995) also reported that two
patients with the A-*G transition in codon 213 experienced a very
poor survival, but more studies on this silent third base mutation in
Arg-213 will be needed to clarify these observations. We also
observed that the different TP53 gene mutations in primary breast
cancer could be related to differences in (relapse-free) survival, for
example our study shows that mutations that directly contact DNA
are related with a poor (relapse-free) survival of breast cancer
patients. This does not agree with data from B0rresen et al (1995).
These authors reported that, in a multicentre study, patients with
TP53 mutations in the zinc-binding domains (L2 and L3) had a
poor prognosis. One possible explanation for the observed differ-
ence could be the shorterfollow-up time in their study (median: 40
months vs 115 months in this study). In conclusion, the analysis of
type and location ofTP53 alterations can be used to select residues
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Figure 2 Actuarial relapse-free (A and C) and overall (B and D) survival as a function of TP53 gene mutation. A and B WT, wild-type (n = 124 patients); mut,
mutated in exons 5 to 8 (n = 53 patients). C and D non dir DNA, no direct contact of the affected codon with the DNA strand (n = 43 and ten patients
respectively).
that could be of prognostic value. If these data are confirmed by
other investigators in larger studies, the use of artificially or natu-
rally created restriction sites or allele-specific oligo techniques can
facilitate the detection ofthese DNA contact residues.
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